Carmen Maria Cabrera
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Carmen Maria Cabrera has a total of 22 co-authors. Here are the top co-authors by number of shared publications:
- José Miguel Urra
Immunology Hospital General Universitario de Ciudad Real Ciudad Real Spain
4 shared publications Abelardo Caballero
A Department of Hematology, Immunology Section , Carlos Haya Regional University Hospital , Málaga , Spain
1 shared publication- Agustín Carreño
Servicio de Nefrología, Hospital General Universitario de Ciudad Real, SESCAM, Ciudad Real, España
1 shared publication Alberto Palacios-Cañas
Allergy Section, Ciudad Real University General Hospital, Ciudad Real, Spain
1 shared publicationAlberto Palacios‐Cañas
Allergy Section Ciudad Real University General Hospital Ciudad Real Spain
1 shared publicationAndrea Castiblanque
Faculty of Medicine of Ciudad Real, University of Castilla-La Mancha, Ciudad Real, Spain
1 shared publication
Latest Publications
- Open Access
- 29 July 2026
- Published by Elsevier in SSRN Electronic Journal
Clinical utility of the urinary free light chain assay in monoclonal gammopathies and patients with chronic kidney disease
To date, urine protein electrophoresis (UPE) is the only recommended technique for measuring FLCs in 24-hour urine samples from monoclonal gammopathies, although it has low diagnostic sensitivity. The Freelite assay for FLCs is available as an alternative method, although very few studies in urine have been conducted on it. The FLC assay was investigated in 24-hour urine samples from patients with different monoclonal gammopathies (N = 180) and a second group with polyclonal FLCs consisting of 79 samples from patients with CKD. In the monoclonal gammopathies group, the mean values of both kappa and lambda FLCs showed higher levels compared to UPE (p = 0.009 and p = 0.015, respectively), and a positive correlation was also found between both techniques (free kappa: r = 0.289, p = 0.038; free lambda: r = 0.921, p < 0.001). ROC curve analysis showed that for both kappa and lambda FLCs, the urine FLC assay had greater diagnostic accuracy compared to UPE (kappa: AUC = 0.919 vs. AUC = 0.819, lambda: AUC = 0.970 vs. AUC = 0.869; respectively). Conversely, in the CKD group, the mean values of polyclonal FLCs were higher with the UPE compared to FLC assay in urine (p = 0.034), and protein levels showed no correlation between the two techniques. Furthermore, the UPE showed greater diagnostic accuracy than urine FLC analysis (AUC = 0.957 vs. AUC = 0.852, respectively). Therefore, the FLC assay (Freelite) is a suitable method for measuring monoclonal FLCs in urine, but not for quantifying polyclonal FLCs.
- 29 July 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessClinical utility of the urinary free light chain assay in monoclonal gammopathies and patients with chronic kidney disease
To date, urine protein electrophoresis (UPE) is the only recommended technique for measuring FLCs in 24-hour urine samples from monoclonal gammopathies, although it has low diagnostic sensitivity. The Freelite assay for FLCs is available as an alternative method, although very few studies in urine have been conducted on it. The FLC assay was investigated in 24-hour urine samples from patients with different monoclonal gammopathies (N = 180) and a second group with polyclonal FLCs consisting of 79 samples from patients with CKD. In the monoclonal gammopathies group, the mean values of both kappa and lambda FLCs showed higher levels compared to UPE (p = 0.009 and p = 0.015, respectively), and a positive correlation was also found between both techniques (free kappa: r = 0.289, p = 0.038; free lambda: r = 0.921, p < 0.001). ROC curve analysis showed that for both kappa and lambda FLCs, the urine FLC assay had greater diagnostic accuracy compared to UPE (kappa: AUC = 0.919 vs. AUC = 0.819, lambda: AUC = 0.970 vs. AUC = 0.869; respectively). Conversely, in the CKD group, the mean values of polyclonal FLCs were higher with the UPE compared to FLC assay in urine (p = 0.034), and protein levels showed no correlation between the two techniques. Furthermore, the UPE showed greater diagnostic accuracy than urine FLC analysis (AUC = 0.957 vs. AUC = 0.852, respectively). Therefore, the FLC assay (Freelite) is a suitable method for measuring monoclonal FLCs in urine, but not for quantifying polyclonal FLCs.
- 23 May 2025
- Published by Elsevier in Clinica Chimica Acta
- Vol. 575, 120383
Associations between biological markers and haematological manifestations in patients with systemic lupus erythematosus
- 23 May 2025
- Published by Elsevier in Clinica Chimica Acta
- Vol. 575, 120383
Associations between biological markers and haematological manifestations in patients with systemic lupus erythematosus
- Open Access
- 28 August 2023
- Published by Wiley in Journal of Clinical Laboratory Analysis
- Vol. 37 (15-16) , e24960
Would the choice of multiplex platform impact the management of the allergic patient? A first approach focusing on LTPs
Background: In the Mediterranean area, patients with LTP syndrome who are sensitized to multiple allergens are often tested for sIgE using multiplex platforms. The results obtained from different commercial platforms are not interchangeable, so it is important to compare and validate the platform selected for use. The objective of this study is to compare and validate the performance of the ImmunoCAP ISAC E112i and the macroarray ALEX2 in our daily practice.Methods: From August 2021 to March 2022, we tested 20 random serum samples from polysensitized patients using the ALEX2 test (MADx) and ImmunoCAP tIgE and ISAC E112i (Thermo Fisher Scientific). We compared the total IgE (tIgE) and sIgE levels for shared allergens.Results: The heatmap generally showed more intense results for ISAC. The overall correlation was good, but some exceptions were noted. The main discrepancies were found for Ole e 7, which was positive for 11 patients in ISAC but negative for all patients in ALEX2, and for nut LTPs, for which ISAC showed a threefold higher detection rate for Ara h 9 and a fivefold higher detection rate for Cor a 8 and Jug r 3 compared to ALEX2. The regression model showed no interchangeability of tIgE results.Conclusions: Despite our small sample size and the complexity of comparing a quantitative and a semi‐quantitative platform, our results suggest that patient diagnosis and management can be influenced by the platform used. Therefore, our findings must be taken into consideration when choosing a platform to use for some profiles of LTP‐polysensitized patients, even though more data is needed.
- 28 August 2023
- Published by Wiley in Journal of Clinical Laboratory Analysis
- Vol. 37 (15-16) , e24960
Open AccessWould the choice of multiplex platform impact the management of the allergic patient? A first approach focusing on LTPs
Background: In the Mediterranean area, patients with LTP syndrome who are sensitized to multiple allergens are often tested for sIgE using multiplex platforms. The results obtained from different commercial platforms are not interchangeable, so it is important to compare and validate the platform selected for use. The objective of this study is to compare and validate the performance of the ImmunoCAP ISAC E112i and the macroarray ALEX2 in our daily practice.Methods: From August 2021 to March 2022, we tested 20 random serum samples from polysensitized patients using the ALEX2 test (MADx) and ImmunoCAP tIgE and ISAC E112i (Thermo Fisher Scientific). We compared the total IgE (tIgE) and sIgE levels for shared allergens.Results: The heatmap generally showed more intense results for ISAC. The overall correlation was good, but some exceptions were noted. The main discrepancies were found for Ole e 7, which was positive for 11 patients in ISAC but negative for all patients in ALEX2, and for nut LTPs, for which ISAC showed a threefold higher detection rate for Ara h 9 and a fivefold higher detection rate for Cor a 8 and Jug r 3 compared to ALEX2. The regression model showed no interchangeability of tIgE results.Conclusions: Despite our small sample size and the complexity of comparing a quantitative and a semi‐quantitative platform, our results suggest that patient diagnosis and management can be influenced by the platform used. Therefore, our findings must be taken into consideration when choosing a platform to use for some profiles of LTP‐polysensitized patients, even though more data is needed.
- 13 March 2023
- Published by Elsevier in International Immunopharmacology
- Vol. 117, 110000
Clinical validation of the basophil activation test in immediate hypersensitivity reactions to gadolinium-based contrast agents
- 13 March 2023
- Published by Elsevier in International Immunopharmacology
- Vol. 117, 110000
Clinical validation of the basophil activation test in immediate hypersensitivity reactions to gadolinium-based contrast agents
- 27 August 2022
- Published by Elsevier in Clinica Chimica Acta
- Vol. 535, 112-119
Feasibility of the ALEX multiplex platform in the diagnosis of nut allergy from a Mediterranean population
- 27 August 2022
- Published by Elsevier in Clinica Chimica Acta
- Vol. 535, 112-119
Feasibility of the ALEX multiplex platform in the diagnosis of nut allergy from a Mediterranean population
- 1 July 2022
- Published by AVES YAYINCILIK A.Ş. in Turkish Journal of Gastroenterology
- Vol. 33 (7) , 625-626
Association Between Allergic Conditions and Celiac Disease in Pediatric Patients
Cite this article as: Cabrera CM. Association between allergic conditions and celiac disease in pediatric patients. Turk J Gastroenterol. 2022;33(7):625-626.
- 1 July 2022
- Published by AVES YAYINCILIK A.Ş. in Turkish Journal of Gastroenterology
- Vol. 33 (7) , 625-626
Association Between Allergic Conditions and Celiac Disease in Pediatric Patients
Cite this article as: Cabrera CM. Association between allergic conditions and celiac disease in pediatric patients. Turk J Gastroenterol. 2022;33(7):625-626.
- 22 April 2022
- Published by Elsevier
- Vol. 109, 129-163
Oligoclonal bands: An immunological and clinical approach
- 22 April 2022
- Published by Elsevier
- Vol. 109, 129-163
Oligoclonal bands: An immunological and clinical approach
- 1 December 2020
- Published by Elsevier in Journal of Immunological Methods
- Vol. 487, 112898
Semi-automated methodology for detection of IgM oligoclonal bands in cerebrospinal fluid and serum samples
- 1 December 2020
- Published by Elsevier in Journal of Immunological Methods
- Vol. 487, 112898
Semi-automated methodology for detection of IgM oligoclonal bands in cerebrospinal fluid and serum samples
- 6 July 2020
- Published by Wiley in Acta Paediatrica
- Vol. 110 (1) , 335-336
Involvement of clinical characteristics and HLA‐DQ2 genotypes in paediatric patients with coeliac disease suffering from allergies
The first description on the association of coeliac disease (CD) with allergic conditions dates in the 1970s, when was found the co‐occurrence of asthma, eczema and rhinitis in adult patients with CD. Later, this likely connection was screened both in paediatric and adult populations, although with conflicting results (1,2). Hence, the relationship between CD and allergy is scarcely known.
- 6 July 2020
- Published by Wiley in Acta Paediatrica
- Vol. 110 (1) , 335-336
Involvement of clinical characteristics and HLA‐DQ2 genotypes in paediatric patients with coeliac disease suffering from allergies
The first description on the association of coeliac disease (CD) with allergic conditions dates in the 1970s, when was found the co‐occurrence of asthma, eczema and rhinitis in adult patients with CD. Later, this likely connection was screened both in paediatric and adult populations, although with conflicting results (1,2). Hence, the relationship between CD and allergy is scarcely known.
- 30 July 2019
- Published by Taylor & Francis in Scandinavian Journal of Gastroenterology
- Vol. 54 (8) , 960-964
Is the double gene dose of DQ2.5 or DQ2.5/DQ2.2 an involved factor in the clinical features of celiac disease?
Objectives: Celiac disease (CD) is barely known if the quantitative effect of DQB1*02 (DQ2) double dose in antigen presentation to T-cells has translation into the clinic. For this, we have conducted a case-control study in a cohort of two hundred and nineteen patients with CD. Material and methods: For the control group, individuals were enrolled with single dose of DQ2, carrying DQ2.5 heterodimers in heterozygous state (n = 109). The cases with CD were diving into three groups: cases with overall DQ2 double dose (n = 110), DQ2.5 homozygous (n = 33) and DQ2.5/DQ2.2 heterozygous (n = 77). Prevalence and associations of demographic, laboratory, histological and clinical characteristics between the control group and cases were studied. Results: No differences were found for the total of 16 variables analyzed between the control group and overall DQ2 double dose as well as DQ2.5 homozygous cases. In contrast to DQ2.5/DQ2.2, heterozygous cases presented a protection factor for developing allergy to airway allergens regarding the control group (OR = 0.210, p = .019). Conclusions: To date, this negative association has not been described. Further studies will be necessary to elucidate the implication of this protection factor in CD. Since, until now the association between CD and allergic diseases has been poorly studied.
- 30 July 2019
- Published by Taylor & Francis in Scandinavian Journal of Gastroenterology
- Vol. 54 (8) , 960-964
Is the double gene dose of DQ2.5 or DQ2.5/DQ2.2 an involved factor in the clinical features of celiac disease?
Objectives: Celiac disease (CD) is barely known if the quantitative effect of DQB1*02 (DQ2) double dose in antigen presentation to T-cells has translation into the clinic. For this, we have conducted a case-control study in a cohort of two hundred and nineteen patients with CD. Material and methods: For the control group, individuals were enrolled with single dose of DQ2, carrying DQ2.5 heterodimers in heterozygous state (n = 109). The cases with CD were diving into three groups: cases with overall DQ2 double dose (n = 110), DQ2.5 homozygous (n = 33) and DQ2.5/DQ2.2 heterozygous (n = 77). Prevalence and associations of demographic, laboratory, histological and clinical characteristics between the control group and cases were studied. Results: No differences were found for the total of 16 variables analyzed between the control group and overall DQ2 double dose as well as DQ2.5 homozygous cases. In contrast to DQ2.5/DQ2.2, heterozygous cases presented a protection factor for developing allergy to airway allergens regarding the control group (OR = 0.210, p = .019). Conclusions: To date, this negative association has not been described. Further studies will be necessary to elucidate the implication of this protection factor in CD. Since, until now the association between CD and allergic diseases has been poorly studied.